Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid
by Zacks Equity Research
Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.
Should Value Investors Consider Gilead Sciences (GILD) Stock?
by Zacks Equity Research
Gilead Sciences (GILD) appears to be a good choice for value investors right now, given its favorable metrics and estimate revisions.
4 Biotech Stocks That Show Promise on Sustainable Growth
by Zacks Equity Research
Biotech sector is performing well in 2017 due to an increase in FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strong performance of legacy products.
Options Traders Expect Huge Moves in Gilead Sciences (GILD) Stock
by Zacks Equity Research
Gilead Sciences (GILD) needs Investors to pay close attention to the stock based on moves in the options market lately.
3 Pharma/Biotech Sector Bargains for a Healthy Portfolio
by Zacks Equity Research
The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.
The Zacks Analyst Blog Highlights: Gilead, Oracle, Morgan Stanley, Expedia and Kroger
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, Oracle, Morgan Stanley, Expedia and Kroger
5 Top-Ranked Biotech Stocks to Buy Right Now
by Arpita Dutt
If you are looking to invest in the biotech sector, here is a peek at 5 buy-ranked biotech stocks including Regeneron Pharmaceuticals (REGN).
Top Ranked Income Stocks to Buy for September 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, September 8th:
Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus
by Zacks Equity Research
With the approval of Novartis AG' (NVS) Kymriah, investors have started to shift their focus on a number of companies which have been developing their pipeline candidates.
Mallinckrodt Down as District Court Invalidates Inomax Patents
by Zacks Equity Research
Shares of Mallinckrodt plc (MNK) were down 12.3% after a U.S. District Court invalidated 11 patents covering its second-largest product Inomax.
Buy These 5 Large Caps on Extraordinary ROI Potential
by Zacks Equity Research
Amid heightening tensions in the Korean Peninsula and hurricanes back home, let's take the safer route and invest for the long haul, using ROI as a barometer.
4 Biotech Stocks to Improve Your Portfolio's Health
by Zacks Equity Research
The biotech industry has posted a turnaround in the first half of the year, despite facing pricing issues in 2016.
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Activision Blizzard, Intuit, Alexion Pharmaceuticals and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Activision Blizzard, Intuit, Alexion Pharmaceuticals and Gilead Sciences
Biotech Stocks Back in Favor: Will the Rally Continue?
by Arpita Dutt
Interest in the biotech sector has picked up with the Gilead (GILD)-Kite acquisition announcement. Will the rally continue?
Valeant (VRX) Continues to Lose Ground: Can It Bounce Back?
by Zacks Equity Research
Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services and woes do not end.
Gilead Buys Kite, the Future of CAR-T, and A Visit to the New Whole Foods
by Ryan McQueeney
On today's episode of the Zacks Friday Finish Line, Content Writer Ryan McQueeney and Editor Maddy Johnson take on this week's biggest stories, including Gilead's acquisition of Kite Pharma, the future of the CAR-T therapy industry, and Amazon's changes to Whole Foods stores.
Novartis (NVS) CAR-T Therapy Kymriah Receives FDA Approval
by Zacks Equity Research
Novartis AG (NVS) gets a major boost as the FDA approved its breakthrough gene transfer treatment, Kymriah for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL).
Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update
by Arpita Dutt
It's all about CAR-T stocks this week with Gilead (GILD) announcing its intention to acquire Kite Pharma for $11.9 billion and Novartis gaining FDA approval for the first CAR-T cell therapy.
Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap
by Ryan McQueeney
The cancer treatment industry is celebrating a massive victory on Wednesday, as Novartis (NVS) received approval for its innovative new lymphoblastic leukemia treatment, making it the first approved CAR-T therapy in the world.
Zacks.com featured highlights Broadcom, CBRE Group, Sandvik, Applied Materials and Gilead Sciences
by Zacks Equity Research
Zacks.com featured highlights Broadcom, CBRE Group, Sandvik, Applied Materials and Gilead Sciences
Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal
by Zacks Equity Research
Gilead's (GILD) $11.8 billion deal to buy Kite Pharma KITE) has made two other leading independent CAR-T developers, Juno and Bluebird Bio hot takeover targets.
The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG
Gilead (GILD) Up 2.1% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Gilead (GILD) reported earnings about a month ago. What's next for the company? We take a look at earnings estimates for some clues.
Indecision Won't Kill You, But It Will Take Your Money
by Kevin Cook
The pitfalls and powers of decision-making for traders and investors could be a model for everyone else.
Gilead to Fly High with Kite Pharma Acquisition for $11.9B
by Zacks Equity Research
Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy.